GlassScriptPhysician profile
Deborah J Rich
NPI 1023050531
$4,620.69
in general payments reported to CMS, 2019-2025
27 companies · $1,249 in 2025
The $1,249 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,525 · 2024: $1,847 · 2025: $1,249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,621.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,620.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,145.46 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $580.54 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $491.32 | 2023-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $344.54 | 2023-2025 | |
| Pfizer INC. | $239.11 | 2023-2025 | |
| Lilly USA, LLC | $227.08 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $200.99 | 2023-2025 | Jardiance, Synjardy, Tradjenta |
| Phathom Pharmaceuticals, INC. | $146.53 | 2024-2025 | Voquezna |
| Abbott Laboratories | $140.01 | 2023-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $119.39 | 2024 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $115.61 | 2023-2024 | Trulance, Xifaxan |
| Alkermes, INC. | $111.06 | 2023 | Aristada, Aristada Initio, Vivitrol |
| Sumitomo Pharma America, INC. | $107.08 | 2024-2025 | Gemtesa |
| Glaxosmithkline, LLC. | $100.06 | 2023-2024 | Trelegy Ellipta, Arexvy |
| Vanda Pharmaceuticals INC. | $98.25 | 2023 | Hetlioz, Fanapt |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $96.82 | 2023-2025 | |
| Inspire Medical Systems, INC. | $92.22 | 2024 | Inspire |
| Idorsia Pharmaceuticals US INC | $53.15 | 2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $37.27 | 2023 | Trintellix |
| Insightec,INC | $32.43 | 2025 | Exablate |
| Actelion Pharmaceuticals US, INC. | $30.53 | 2025 | Uptravi, Opsumit |
| Corcept Therapeutics | $29.14 | 2024 | Korlym |
| Mylan Specialty L.P. | $24.72 | 2023 | Yupelri |
| Echosens North America, INC. | $14.71 | 2025 | Fibroscan |
| Xeris Pharmaceuticals, INC. | $14.57 | 2024 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $14.06 | 2023 | Gardasil 9, M-M-R II |
| Esperion Therapeutics, INC. | $14.04 | 2024 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Rich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.